Many of them are on Medicaid and have become yo-yo dieters who, despite their best efforts at changing their eating habits and lifestyles, cannot seem to shed the pounds hurting their health. “They ...

The podcast features Numerator Chief Economist Leo Feler, who talks about the potential impact of GLP-1 drugs like Ozempic ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

By coincidence (they started before GLP -1 drugs were approved for slimming), a group of 56 doctors have just answered that ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...